A Phase 3 interventional study of Remibrutinib and Placebo to remibrutinib in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 110 sites in 23 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.
Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 9th registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, Hong Kong, Japan and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United States, France, Germany and 2 more countries
Ages 18+
By country, each count listing its studies:
remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, remibrutinib is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 470 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 347 across the 12 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
38 studies in Chronic Urticaria by Novartis: 7 open now, 12 under way, 5 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 38 studies in Chronic Urticaria by Novartis, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 27th registered.
Novartis’s Chronic Urticaria studies by the year they started, since 2007.
2 of the studies testing remibrutinib in Chronic Urticaria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT06865651Novartis PharmaceuticalsStudy of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | 2027-08-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing remibrutinib in Chronic Urticaria, from their registry updates:
Among Novartis’s 38 in Chronic Urticaria:
This tab as a report to print or save as PDF → With an account.
The purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines (H1-AH).
The purpose of the open-label extension phase is to assess efficacy, safety and tolerability up to two years for patients treated with remibrutinib and patients transitioned from omalizumab to remibrutinib at Week 52. In the extension phase, treatment will be with remibrutinib only (i.e., no background therapy). The extension phase will also fulfill the Novartis commitment to provide post-trial access to participants of the previous core phase.
The study consists of 4 periods, and the total study duration is up to 112 weeks. Approximately 468 adult participants with CSU are expected to be randomized in the study.
Screening period: A screening period of up to 4 weeks will allow for the assessment of eligibility, determination of baseline disease activity and wash-out of prohibited medications.
Core Phase Treatment Period (52 weeks):
The treatment period will be double-dummy and double-blind, with placebo injections matching omalizumab 300 mg s.c. given to participants in the remibrutinib arm and placebo tablets matching remibrutinib 25 mg given to participants in the omalizumab arm (double-dummy). At the randomization visit, eligible participants will be randomized to one of four treatment arms.
Extension Phase Treatment Period (52 weeks): Optional open-label extension where patients receive treatment with open-label remibrutinib 25 mg, for 52 weeks.
Follow-up period:
For patients that do not enter the extension phase, there will be a 16-week, treatment-free, safety follow-up period.
Patients that enter extension phase will have a 4-week treatment-free safety follow-up period at the end of the extension phase.
All participants will be on a stable, local label-approved standard dose of a second-generation H1-AH ("background therapy") throughout the entire core phase (starting a minimum of 7 days prior to randomization until the end of the core phase).
In addition, to treat unbearable symptoms of CSU flare-ups, participants will be allowed to use a different second-generation H1-AH on an as-needed basis ("rescue therapy").
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 52 weeks.
Drug: Remibrutinib
Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w.
Drug: Placebo to remibrutinib
Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d.
Drug: Placebo to omalizumab
participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d. for 52 weeks.
Drug: Omalizumab
Active treatment
Placebo followed by active treatment
Placebo followed by active comparator
Active comparator
Absolute change from baseline in Weekly Urticaria Activity Score (UAS7)
The UAS7 is the sum of the Weekly Hives Severity Score (HSS7 score) and the Weekly Itch Severity Score (ISS7 score). The possible range of the weekly UAS7 score is 0 - 42 (highest activity).
Time frame: Week 12
Achievement of UAS7=0 (yes/no)
Complete UAS7 response is UAS7 = 0
Time frame: Week 12
Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score
The severity of the itch will be recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21.
Time frame: Week 12
Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score
The hives (wheals) severity score, defined by number of hives, will be recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21.
Time frame: Week 12
Occurrence of treatment-emergent adverse events and serious adverse events (SAEs)
To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)
Time frame: up to 68 weeks
Showing the first 100 of 110 sites across 23 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Sep 2025, 22 months.
Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 22 months is close to that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib